(Q51471980)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

The toronto observational study of natalizumab in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Paul W O'Connor

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

422-428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Observations during an elective interruption of natalizumab treatment: a post-marketing study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

The pathophysiologic role of alpha 4 integrins in vivo

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011811

7 January 2021

10.1017/S0317167100011811

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515500%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference